drugset / Trial / NCT03981562

Vitamin D and Hereditary Haemorrhagic Telangiectasia

NCT03981562

Phase 2 Unknown 60 enrolled St. Paul's Hospital, Canada
RandomizedParallel-groupDouble-blindTreatment

Summary

The study aims to assess whether supplementing vitamin D in patients diagnosed with Hereditary Haemorrhagic Telangiectasia (HHT) will decrease the frequency and severity of nosebleeds these patients experience. It is hypothesized that the larger the dose of daily vitamin D given to the patients, the less frequent and less severe the nosebleeds will be.

Timeline

Start
2018-07-16
Primary completion
2020-07-01
Completion
2020-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin D Other / unclassified 1000 iu Oral
Subject Vitamin D Other / unclassified 4000 iu Oral